Remedy Robotics
Remedy Robotics is a surgical robotics company that has developed the world's first remotely operable endovascular robot, primarily targeting stroke treatment to make endovascular care accessible globally. Their technology enables remote operation of the robot via internet, allowing patients anywhere to receive immediate, high-quality endovascular intervention. The company collaborates with experienced clinicians and experts in surgical robotics and machine learning, and has achieved significant milestones including first in human clinical procedures, integration into hospitals like UCLA, and published clinical trial results. Remedy Robotics operates with a mission-driven approach, combining medical and technical expertise to solve critical healthcare challenges and scale their innovative robotic solutions worldwide.
Remedy Robotics
Remedy Robotics is a surgical robotics company that has developed the world's first remotely operable endovascular robot, primarily targeting stroke treatment to make endovascular care accessible globally. Their technology enables remote operation of the robot via internet, allowing patients anywhere to receive immediate, high-quality endovascular intervention. The company collaborates with experienced clinicians and experts in surgical robotics and machine learning, and has achieved significant milestones including first in human clinical procedures, integration into hospitals like UCLA, and published clinical trial results. Remedy Robotics operates with a mission-driven approach, combining medical and technical expertise to solve critical healthcare challenges and scale their innovative robotic solutions worldwide.
TL;DR
Product: Remedy N1 System — remotely operated endovascular robot with AI-assisted navigation
Clinical milestones: Remote in-vivo trials (2022) and first-in-human procedures (Nov–Dec 2024)
Founders: David Bell and Jake Sganga
Funding: Reported total raised ~$38M; investors include DCVC, Blackbird, KdT Ventures
Company Overview
Problem Domain
Endovascular intervention for neurovascular and cardiovascular conditions, with emphasis on stroke treatment and widening geographic access to care.
Founded
2021
Industry
DeepTech
Tech Stack
Funding Track Record
Seed funding announced May 2021 with participation from KdT Ventures, Pathbreaker Ventures, and Future Shape
Series A announced May 2022 with participation from existing investors including DCVC, KdT Ventures, Pathbreaker Ventures, and Future Shape
Investor Signal
“Investors include DCVC, Blackbird, KdT Ventures, Pathbreaker Ventures, and Future Shape”